Alterity to Discuss Clinical Trial Strategies at Healthcare Summit Ahead of Phase 3 Launch
Alterity Therapeutics CEO David Stamler will present at the Bell Potter Healthcare Horizons Summit on March 12-13 and join a fireside chat on optimizing late-stage clinical trials. Alterity plans a pivotal Phase 3 trial of ATH434 in Multiple System Atrophy after its Phase 2 trial showed clinically meaningful efficacy and positive open-label results.
1. Summit Participation
David Stamler, Chief Executive Officer of Alterity Therapeutics, will attend the Bell Potter Healthcare Horizons Summit on March 12-13, participating in investor meetings and networking with analysts and stakeholders.
2. Fireside Chat on Late-Stage Trials
Stamler will join a fireside chat titled “Optimising Late-stage Clinical Trials to Increase the Odds,” outlining strategies to improve trial design, patient enrollment and regulatory engagement for neurodegenerative therapies.
3. Pivotal Phase 3 Trial Plans
Alterity is preparing to initiate a pivotal Phase 3 trial of ATH434 in Multiple System Atrophy, aiming to advance its lead asset toward regulatory approval and commercialization based on strong early-stage results.
4. Phase 2 Efficacy Data
ATH434 demonstrated clinically meaningful efficacy in a randomized Phase 2 trial and yielded positive safety and outcome measures in an open-label extension, supporting the company’s decision to progress into a larger pivotal study.